Ivacaftor: Long term adherence and outcomes
Listen now
Description
The recent development of triple CFTR modulation means that up to 90% of people with CF will be eligible for ‘highly effective’ CFTR modulator therapy. In this podcast, Rachael Moses, Multimedia Editor of Thorax, and Dr Peter Barry, Consultant Respiratory Physician, Manchester Adult Cystic Fibrosis Centre, discuss the long-term adherence to and effects of ivacaftor on lung function, weight and healthcare utilisation in people with cystic fibrosis and the Gly551Asp mutation.
Read the related paper: https://thorax.bmj.com/content/early/2021/03/24/thoraxjnl-2020-215556
More Episodes
A new clinical statement from the British Thoracic Society was recently published in Thorax. It describes a building-block approach for how to manage patients with tobacco dependency in a hospital setting. Thorax podcast host Dr. Kate Diomede speaks with two of the authors, Prof. Sanjay Agrawal...
Published 06/21/24
What are the effects of high levels of social media consumption amongst young people? New research published in Thorax quantifies the impact that exposure to marketing on online platforms is having, showing a greater likelihood of smoking or vaping with greater time spent on these platforms....
Published 05/16/24
Published 05/16/24
Links
Twitter
Facebook
Instagram
Patreon
Genres
Artwork or description wrong?
Request an update »
Updates may take a few minutes.
Do you host a podcast?
Track your ranks and reviews from Spotify, Apple Podcasts and more.
See hourly chart positions and more than 30 days of history.
Get Chartable Analytics »
See hourly chart positions and more than 30 days of history.
